Active Ingredient History
Carbamazepine is an analgesic, anti-epileptic agent that is FDA approved for the treatment of epilepsy, trigeminal neuralgia. It appears to act by reducing polysynaptic responses and blocking the post-tetanic potentiation. It depresses thalamic potential and bulbar and polysynaptic reflexes, including the linguomandibular reflex in cats. Commonly reported side effects of carbamazepine include: dizziness, drowsiness, nausea, ataxia, and vomiting. Carbamazepine is a potent inducer of hepatic CYP1A2, 2B6, 2C9/19, and 3A4 and may reduce plasma concentrations of concomitant medications mainly metabolized by CYP1A2, 2B6, 2C9/19, and 3A4 through induction of their metabolism, like Boceprevir, Cyclophosphamide, Aripiprazole, Tacrolimus, Temsirolimus and others. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alcoholism (Phase 4)
alpha 1-Antitrypsin Deficiency (Phase 2)
Anxiety Disorders (Phase 3)
Asthma (Phase 4)
Astrocytoma (Phase 1)
Bariatric Surgery (Phase 4)
Bone Diseases, Metabolic (Phase 4)
Cocaine-Related Disorders (Phase 4)
Contraception (Phase 4)
COVID-19 (Phase 1)
Dementia (Phase 3)
Depression (Phase 3)
Drug Interactions (Phase 4)
Drug Resistant Epilepsy (Phase 4)
Drugs, Generic (Phase 1)
Epilepsies, Partial (Phase 4)
Epilepsy ()
Epilepsy, Reflex (Phase 2)
Epilepsy, Rolandic (Phase 4)
Erythromelalgia (Phase 4)
Fasting (Phase 1)
Glioblastoma (Phase 1)
Glioma (Phase 4)
Gliosarcoma (Phase 1)
Healthy Volunteers (Phase 1)
Hepatitis B (Phase 1)
HIV (Phase 1)
HIV Infections (Phase 2)
Intellectual Disability (Phase 4)
Liver Cirrhosis (Phase 2)
Mania (Phase 4)
Metabolic Clearance Rate (Phase 4)
Neuralgia (Phase 4)
Oligodendroglioma (Phase 1)
Osteoporosis (Phase 4)
Parkinson Disease (Phase 1)
Pharmacology, Clinical (Phase 1)
Psychophysiologic Disorders (Phase 3)
Schizophrenia (Phase 3)
Seizures ()
Spasms, Infantile (Phase 2)
Stroke (Phase 3)
Substance-Related Disorders (Phase 4)
Ultrasonography (Early Phase 1)
Vasomotor System (Phase 1)
Wuchereria bancrofti (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
